Xilio Therapeutics, Inc.
Returns on Capital
| Period | ROE | ROI | ROA |
|---|---|---|---|
| Mar 2020 | 21.6% | 21.6% | — |
| Jun 2020 | 23.5% | 23.5% | — |
| Sep 2020 | 23.5% | 23.5% | — |
| Dec 2020 | 24.9% | 24.9% | -57.2% |
| Mar 2021 | 16.8% | 16.8% | — |
| Jun 2021 | 19.1% | 19.1% | — |
| Sep 2021 | 11.9% | 11.9% | -13.5% |
| Dec 2021 | -10.6% | -10.6% | -9.0% |
| Mar 2022 | -12.9% | -12.9% | -10.9% |
| Jun 2022 | -17.1% | -17.1% | -13.8% |
| Sep 2022 | -15.7% | -15.7% | -12.6% |
| Dec 2022 | -21.3% | -21.3% | -16.1% |
| Mar 2023 | -26.7% | -26.7% | -20.3% |
| Jun 2023 | -28.7% | -28.7% | -21.0% |
| Sep 2023 | -31.9% | -31.9% | -21.5% |
| Dec 2023 | -47.9% | -47.9% | -29.0% |
| Mar 2024 | -66.8% | -66.8% | -20.8% |
| Jun 2024 | -41.7% | -41.7% | -15.5% |
| Sep 2024 | -66.8% | -66.8% | -18.8% |
| Dec 2024 | -74.4% | -74.4% | -18.4% |
| Mar 2025 | -124.0% | -124.0% | -12.8% |
| Jun 2025 | -224.1% | -224.1% | -11.8% |
| Sep 2025 | 201.2% | 201.2% | -12.2% |
| Dec 2025 | 29.4% | 29.4% | 6.7% |
| Mar 2026 | -13.1% | -13.1% | -5.8% |
| Jun 2026 | -8.8% | -8.8% | -4.1% |